'use of synaptic vesicle protein inhibitor 2a (sv2a), valproate, levetiracetam, brivarecetam and seletracetam in the treatment of cognitive impairment, as well as pharmaceutical composition comprising the same'

摘要

Methods and Compositions for Enhancing Cognitive Function The present invention relates to methods and compositions for treating cognitive impaired central nervous system (snc) disorders. in particular, it refers to the use of synaptic vesicle glycoprotein 2a (sv2a) inhibitors alone or in combination with valproate in the treatment of cognitive impaired central nervous system (snc) disorders in an individual in need or at risk including but not limited to individuals having or at risk of age-related cognitive impairment, mild cognitive impairment (mci), amnestic mci (amci), age-related memory impairment (aami), cognitive impairment age (arcd), dementia, alzheimer's disease (ad), prodromal ad, posttraumatic stress disorder (ptsd), schizophrenia, amyotrophic lateral sclerosis, and cognitive impairment related to cancer therapy.